Shine makes 1st commercial sales of Lu-177

By staff writers

November 4, 2020 -- Medical isotope firm Shine Medical Technologies made its first commercial sales of its lutetium-177 (Lu-177) therapeutic isotope to multiple customers.

Numerous clinical trials are underway for Lu-177, a low-energy beta-particle emitter that works by directly irradiating cancer cells after they are delivered to a cancer site by a targeting molecule. Lu-177 is used to treat neuroendocrine cancers.

Currently, Shine is producing the isotope at a small building on its campus. Groundbreaking for a larger facility, which will be capable of producing more than 300,000 doses of Lu-177 per year, is expected in November.

Copyright © 2020

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking